1. Home
  2. Immunoassay Kits for IVD and Research Use
  3. Rapid Tests
  4. GenScript cPass SARS-COV-2 Neutralization Antibody Detection Kit

GenScript cPass SARS-COV-2 Neutralization Antibody Detection Kit


96 Tests

Please confirm that you understand the following statements before placing an order for any of our Rapid Test Kits.

SKU: BSV-L00847-C-96

The GenScript cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit is the first-in-the-world “rapid smart test kit”, with the capability of measuring functional neutralizing antibodies (Nabs) within an hour in most research or clinical labs. It is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating a prior infection.

Authorised distributor of

Key Benefits

The GenScript cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit is faster, easier, more scalable and automatable alternative to the traditional neutralizing antibody tests, such as virus neutralization test (VNT), pseudo-virus neutralization test (pVNT) and plaque reduction neutralization test (PRNT). These tests require the use of live virus, cells, highly skilled operators, and complex safety laboratory procedures (biosafety level 3) that are generally less sensitive and require several days to obtain results. In contrast, the cPass™ Neutralization Antibody Detection Kit can be rapidly conducted within an hour in most labs, and is also amenable to high throughput and fully automated testing.

Another key advantage of the cPass™ technology is that it is a highly specific and sensitive and in the same time isotype- and species-independent. Current antibody tests on the market are typically isotype-specific for just IgM or IgG, species specific for human antibodies only and cannot distinguish NAbs from other binding antibodies which do not possess neutralizing function.

Research Applications

This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine neutralizing antibodies in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals. The cPass™ Neutralization Antibody Test is for research use only. Not for diagnostic use.

Publications showing value of the cPass Technology over gold standard serological tests

1. Tan S.S et al. Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays. Pathology. 2020. 52(7): 770-777.

2. Meyer, B. et al. Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT). medRxiv. 2020. 9(1): 2394-2403.

3. Bal A, et al. Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical sensitivity, specificity and association with virus neutralization test. Clin Chem. 2021 Jan 5: hvaa336.